Source: Health Products Regulatory Authority (IE) Revision Year: 2018 Publisher: Henry Schein UK Holdings Limited, Medcare House, Centurion Close Gillingham Business Park, Gillingham Kent, ME8 0SB, United Kingdom
Minocycline hydrochloride has in vitro antibacterial activity against a wide range of gram-negative and gram-positive organisms thought to be related to periodontal disease, including Porphyromonas gingivalis (formerly Bacteroides gingivalis), Prevotella intermedia (formerly Bacteroides intermedius) and Actinobacillus actinomycetemcomitans, as well as Wolinella recta, Peptostreptococcus spp, Fusobacterium nucleatum and Eikenella corrodens and Spirochaetes.
In a pharmacokinetic study, concentrations of minocycline in gingival crevicular fluid remained at clinically-effective levels for a minimum of three days following the administration of 0.05g gel (1mg minocycline) into periodontal pockets.
Serum levels after subgingival administration and even after direct oral administration of 0.5g gel (10mg minocycline) were only in the range of 0.1-0.2μg/ml. These levels are much lower than the serum levels which would be associated with the normal oral dose of 100-200mg/day minocycline used in systemic therapy. To demonstrate this, DENTOMYCIN following the fourth application has a Cmaxa (mean) of 0.10 μg/ml, whereas MINOCIN 50 mg Tablets administered 12 hourly result in steady state levels Cmax (mean) of 2.08 μg/ml and Cminb (mean) of 1.09 μg/ml.
a Cmax = maximum serum concentration.
b Cmin = minimum serum concentration.
Nothing of further relevance to the prescriber.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
